Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV 1 protease inhibitors prevention by alternating several antiproteases in short sequences

Biomedicine and Pharmacotherapy

Volumn 53, Issue 10, 1999, Pages 449-451

  Mathe G ^a  

^a Lab 'Rythmes Biologiques C   (France)

Author keywords

CRAB1; HIV 1 protease inhibitors; Lipodysplasia prevalence in antiprotease; LRP

Indexed keywords

PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0033397386     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88101-9     Document Type: Editorial

References (34)

1. Mathé G, Richet G. Semiologie. 4th Ed. Flammarion: Paris; 1981.
2. Mathé G. L'homme qui Voulait être Guéri. 2nd Ed. Anthropos: Paris; 1985.
3. Fliers JS, Kahn CR, Roth J, et al. Antibodies that impair insulin receptor binding in an unsusual diabetic syndrome with severe insulin resistance. Science 1975; 190 : 63-5.
4. Kaplan NP. Upper-body obesity, glucose intolerance, hypertriglycerida and hypertension. Arch Intern Med 1989; 149 : 1514-20.
5. 1 -protease-inhibitors: A review for clinicians. JAMA 1997; 277 : 145-53.
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12 : F51-8.
7. 1 -protease inhibitor associated with peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351 : 1881-3.
8. 1 -protease inhibitor associated lipodystrophy, hyperlipidemia and diabetes mellitus: A cohort study. Lancet 1999; 353 : 2093-9.
9. 1 infection. Lancet 1998; 351 : 867-70.
10. Herry P, Bernard L, de Prucnis P, Perrone C. Hypertrophy of the breast in a patient treated with indinavir. Clin Infect Dis 1997; 25 : 937-8.
11. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Fallon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351 : 871-5.
12. Epstein M. Diabetes and hypertension: The bad companions. J Hypert 1997; 15 Suppl : S55-62.
13. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351 : 1328-000.
14. Li E, Norris AU. Structure function of cytoplasmic vitamin A-binding proteins. Ann Rev Nutr 1996; 16 : 205-34.
15. Fahl M, Chytil F. Regulation of metabolism by retinoic acid and its receptors. Ann Rev Nutr 1996; 16 : 257-83.
16. Dreyfus JC. Glycogenesis. In: Schapira G, Dreyfus JC, eds. Pathologie Moléculaire. Masson: Paris; 1975. p. 182-218.
17. National task force in the prevention and treatment of obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276 : 1907-15.
18. Gaede P, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminura: The steno type 2 randomized study. Lancet 1999; 353 : 617-22.
19. Khoury P, Morrisson JA, Mellies M, Glueck CJ. Weight change since age 18 years in 30-to-55-year-old whites and blacks, associated with lipid values, lipoprotein levels, and blood pressure. JAMA 1983; 250 : 3179-87.
20. Burke JL, Webber LS, Srinivasan SR, Radhakrishnamurthy B, Freedman DS, Berenson GS. Fasting plasma glucose and insulin levels and their relationship to cardiovascular risk factors in children. Bogalusa Heart Study Metabolism 1986; 35 : 441-6.
21. Kennedy BP. Role of protein tyrosine phosphatase-1B in diabetes and obesity. Biomed Pharmacother 1999; this issue.
22. Krotkiewski M, Mandroukas K, Sjögren L, et al. Effect of Long Term Physical Training on Body Fat, Metabolism and Blood Pressure in Obesity Metabolism. 1979; 28 : 650-8.
23. McCarthy M. Lipid-lowering therapy may reduce thrombosis risk. Lancet 1997; 349 : 703.
24. Storlien L-H, Kraegen EW, Chishlom DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 1987; 237 : 885-8.
25. Parillo M, Coulston A, Hollenbeck C, Reaven G. Effect of a low fat diet on carbohydrate metabolism in patients with hypertension. Hypertension 1988; 11 : 244-8.
26. Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetes without alteration of insulin secretion. Lancet 1985; 1 : 123-6.
27. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. J Hypertension 1985; 3 : 297-306.
28. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77 : 1925-30.
29. Lindholm L. Parental obesity combined with hypertension: An indicator of excess risk of hypertension in offspring. Acta Med Scand 1984; 216 : 277-85.
30. Epstein M. Diabetes and hypertension: The bad companions. J Hypertension 1997; 15 Suppl; S55-62.
31. Otsuji, Baba M, Kamada T. Erythrocyte membrane microviscosity in diabetes. Horm Metab Res 1981; 11 Suppl : 97-102.
32. Takahashi M, Seagar MJ, Jones JF, Reber BF, Cattarall WA. Subunit structure of dihydropyridine sensitive calcium channels from skelettal muscle. Proc Natl Acad Sci USA 1987; 84 : 5478-82.
33. Mathé G. Combinations of four virostatics applied in rotational sequences induce an exponential VL regression curve, the first part of which is rapidly decreasing to a PCR-undetectable level, while the last part is insensitive to the model. Indications for virostatic and immunotherapeutic reinforcements? Biomed Pharmacother 1999 : 53 : 57-62.
34. Boyer PD. The Enzymes. 3rd Ed. New York: Acad Press; 1970.